No registrations found.
ID
Source
Brief title
Health condition
Cervical cancer
Lymph nodes
HPV
Cervixcarcinoom
Lymfeklieren
HPV
Sponsors and support
Intervention
Outcome measures
Primary outcome
To analyse the microenvironment of (S)LNs and PT (i.e. antigen presenting cells and other immune cells) and other immune
factors produced by the tumour cells in patients with cervical cancer.
Secondary outcome
- to assess the difference of the microenvironment of tumour-negative and metastatic LNs
- to assess the difference of the microenvironment of SLNs and nonSLNs
- to analyse the difference in the (S)LNs compared to the primary tumour
- to assess the effect of the cervical tumour on the systemic immunity
Background summary
This is an exploratory study to further delineate the microenvironment of the primary tumour and (sentinel) lymph nodes in cervical cancer.All patients diagnosed with cervical carcinoma who will undergo an operation or a lymphadenectomy will be asked to participate in the study. Patients who will undergo a lymphadenectomy will be asked to participate in detecting the SLNs prior to the lymph node dissection by injecting ICG/patent blue in the tumour before the operation starts in the operation room. Patients who will undergo a lymph node debulking in the context of chemoradiotherapy, will be asked permission to obtain a small tumour biopsy.
Study objective
This is an exploratory study to further delineate the microenvironment of the PT and (S)LNs in cervical cancer.
Study design
- blood will be drawn before surgery and 3 months after surgery
Intervention
- patients will be asked to give permission to search for sentinel node(s), by injecting patent blue
- patients will be asked to donate 2x 10 ml blood for further analysis (at two different timepoints)
Jossie Rotman
Obstetrics & Gynecology/Immunotherapy Lab
Amsterdam
The Netherlands
(020-44)42175 Mob: +31622706702
Mail: j.rotman@vumc.nl
Jossie Rotman
Obstetrics & Gynecology/Immunotherapy Lab
Amsterdam
The Netherlands
(020-44)42175 Mob: +31622706702
Mail: j.rotman@vumc.nl
Inclusion criteria
- Age ≥ 18 years at start of the study;
- Primary carcinoma of the cervix;
- Operation at the NKI-AVL or AMC/VUmc;
- Signed informed consent.
Exclusion criteria
- Patients with cervical cancer other than squamous,
adeno- or adenosquamous origin.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL6842 |
| NTR-old | NTR7020 |
| Other | NL62567.031.17 : M17GINC |